CONSORTIUM
Our consortium comprises Cancer Hospitals (Champalimaud, HGUGM and UPMC), technology and data experts (WIT, UNINOVA and Universidad Politécnica de Madrid), and SMEs (Deep Blue, Suite5 Data Intelligence Solutions and TFC Research and Innovation Limited).
FAITH brings together partners from five European countries (Ireland, Portugal, Spain, Italy and Cyprus) into a strong multi-disciplinary team. Brought together, our expertise will allow us to realize our vision of providing intelligent support to patients with depression undergoing cancer treatment.
It hosts the Telecommunications Software & Systems Group (TSSG), an internationally recognized centre of excellence for ICT research and innovation.
WIT is the principal coordinator of the project.
It will lead all management and technical oversight of the project’s delivery.
UPM will oversee the design and implementation of the system architecture, and lead the pilot trials activities.
As end user, its Medical Oncology Service will test the FAITH concept, support the requirements gathering, and provide insights for functional requirements and technical specifications.
It includes the UPMC Hillman Cancer Centre, which has treated more than 17,000 patients.
UPMC Whitfield will actively support the testing of the project, participating in the initial requirements gathering and in the later trials phase.
The CCC offers patient care based on the most advanced technologies. It will be involved in the validation trials of FAITH, including the collection of users’ needs.
Deep Blue will contribute to the collection of requirements and users’ needs, and also lead the dissemination of the project.
Suite5 will support the research and development of the FAITH concept, and investigate the best exploitation paths to ensure it reaches the market.
TFC will lead the standardization and quality management, and also support dissemination, communication, and exploitation.
ADVISORY BOARD
FAITH will avail of the support provided by an External Advisory Board (EAB) to help with the project direction, its research and to ensure that the project outcomes are really useful and effective.
The EAB acts as an independent body, consisting of a group of key stakeholders who have expertise in the field FAITH explores. The External Advisory Board will help with innovation, technological and market acceptance, and take-up opportunities of FAITH, as well as fostering a balanced innovation management process to maximise on scientific excellence, community engagement and exploitation. Specifically, its members will:
- promote and raise awareness of FAITH both within and beyond their organisation and projects;
- offer guidance and feedback on the approach FAITH is taking;
- provide FAITH with information and guidance concerning synergies with the relevant activities of their ongoing work in the healthcare areas.
Overall, the involvement of the EAB through a series of workshops, demonstrations and pilots ensures that the project delivers real valued results and gains exposure for a wider market take-up.
CONSORTIUM
Our consortium comprises Cancer Hospitals (Champalimaud, HGUGM and UPMC), technology and data experts (WIT, UNINOVA and Universidad Politécnica de Madrid), and SMEs (Deep Blue, Suite5 Data Intelligence Solutions and TFC Research and Innovation Limited).
FAITH brings together partners from five European countries (Ireland, Portugal, Spain, Italy and Cyprus) into a strong multi-disciplinary team. Brought together, our expertise will allow us to realize our vision of providing intelligent support to patients with depression undergoing cancer treatment.
It hosts the Telecommunications Software & Systems Group (TSSG), an internationally recognized centre of excellence for ICT research and innovation.
WIT is the principal coordinator of the project.
It will lead all management and technical oversight of the project’s delivery.
UPM will oversee the design and implementation of the system architecture, and lead the pilot trials activities.
As end user, its Medical Oncology Service will test the FAITH concept, support the requirements gathering, and provide insights for functional requirements and technical specifications.
It includes the UPMC Hillman Cancer Centre, which has treated more than 17,000 patients.
UPMC Whitfield will actively support the testing of the project, participating in the initial requirements gathering and in the later trials phase.
The CCC offers patient care based on the most advanced technologies. It will be involved in the validation trials of FAITH, including the collection of users’ needs.
Deep Blue will contribute to the collection of requirements and users’ needs, and also lead the dissemination of the project.
Suite5 will support the research and development of the FAITH concept, and investigate the best exploitation paths to ensure it reaches the market.
TFC will lead the standardization and quality management, and also support dissemination, communication, and exploitation.
CONSORTIUM
Our consortium comprises Cancer Hospitals (Champalimaud, HGUGM and UPMC), technology and data experts (WIT, UNINOVA and Universidad Politécnica de Madrid), and SMEs (Deep Blue, Suite5 Data Intelligence Solutions and TFC Research and Innovation Limited).
FAITH brings together partners from five European countries (Ireland, Portugal, Spain, Italy and Cyprus) into a strong multi-disciplinary team. Brought together, our expertise will allow us to realize our vision of providing intelligent support to patients with depression undergoing cancer treatment.
It hosts the Telecommunications Software & Systems Group (TSSG), an internationally recognized centre of excellence for ICT research and innovation.
WIT is the principal coordinator of the project.
It will lead all management and technical oversight of the project’s delivery.
UPM will oversee the design and implementation of the system architecture, and lead the pilot trials activities.
As end user, its Medical Oncology Service will test the FAITH concept, support the requirements gathering, and provide insights for functional requirements and technical specifications.
It includes the UPMC Hillman Cancer Centre, which has treated more than 17,000 patients.
UPMC Whitfield will actively support the testing of the project, participating in the initial requirements gathering and in the later trials phase.
The CCC offers patient care based on the most advanced technologies. It will be involved in the validation trials of FAITH, including the collection of users’ needs.
Deep Blue will contribute to the collection of requirements and users’ needs, and also lead the dissemination of the project.
Suite5 will support the research and development of the FAITH concept, and investigate the best exploitation paths to ensure it reaches the market.
TFC will lead the standardization and quality management, and also support dissemination, communication, and exploitation.
ADVISORY BOARD
FAITH will avail of the support provided by an External Advisory Board (EAB) to help with the project direction, its research and to ensure that the project outcomes are really useful and effective.
The EAB acts as an independent body, consisting of a group of key stakeholders who have expertise in the field FAITH explores. The External Advisory Board will help with innovation, technological and market acceptance, and take-up opportunities of FAITH, as well as fostering a balanced innovation management process to maximise on scientific excellence, community engagement and exploitation. Specifically, its members will:
- promote and raise awareness of FAITH both within and beyond their organisation and projects;
- offer guidance and feedback on the approach FAITH is taking;
- provide FAITH with information and guidance concerning synergies with the relevant activities of their ongoing work in the healthcare areas.
Overall, the involvement of the EAB through a series of workshops, demonstrations and pilots ensures that the project delivers real valued results and gains exposure for a wider market take-up.